Niki Arya

2.0k total citations · 1 hit paper
14 papers, 1.3k citations indexed

About

Niki Arya is a scholar working on Endocrinology, Diabetes and Metabolism, Surgery and Molecular Biology. According to data from OpenAlex, Niki Arya has authored 14 papers receiving a total of 1.3k indexed citations (citations by other indexed papers that have themselves been cited), including 6 papers in Endocrinology, Diabetes and Metabolism, 5 papers in Surgery and 5 papers in Molecular Biology. Recurrent topics in Niki Arya's work include Diabetes Treatment and Management (6 papers), Pancreatic function and diabetes (5 papers) and Diabetes Management and Research (4 papers). Niki Arya is often cited by papers focused on Diabetes Treatment and Management (6 papers), Pancreatic function and diabetes (5 papers) and Diabetes Management and Research (4 papers). Niki Arya collaborates with scholars based in United States, Sweden and United Kingdom. Niki Arya's co-authors include Alex Z. Fu, Anna Norhammar, Marit E. Jørgensen, Johan Bodegård, Marcus Thuresson, Niklas Hammar, Peter Fenici, Kamlesh Khunti, Matthew A. Cavender and John Wilding and has published in prestigious journals such as Circulation, Journal of Clinical Oncology and Diabetes Care.

In The Last Decade

Niki Arya

14 papers receiving 1.3k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Lower Risk of Heart Failure and Death in Patients Initiated on Sodium-Glucose Cotransporter-2 Inhibitors Versus Other Glucose-Lowering Drugs

2017 604 citations Mikhail Kosiborod, Matthew A. Cavender et al. Circulation profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Niki Arya United States	9	718	575	309	292	154	14	1.3k
Kathrin Heinrich Germany	14	360 0.5×	385 0.7×	362 1.2×	356 1.2×	116 0.8×	69	1.4k
Annie St‐Pierre Canada	12	486 0.7×	510 0.9×	451 1.5×	353 1.2×	66 0.4×	22	1.4k
Cristi R. King United States	12	179 0.2×	379 0.7×	97 0.3×	564 1.9×	64 0.4×	17	1.2k
Mark A. Milad United States	15	187 0.3×	126 0.2×	333 1.1×	175 0.6×	94 0.6×	24	966
Marialuisa Sponziello Italy	22	1.1k 1.5×	707 1.2×	303 1.0×	302 1.0×	144 0.9×	67	1.8k
Stella Santarone Italy	25	134 0.2×	258 0.4×	128 0.4×	414 1.4×	104 0.7×	69	2.1k
Adam W. Grasso United States	5	249 0.3×	261 0.5×	411 1.3×	119 0.4×	190 1.2×	6	883
Lulu Ren Sterling United States	16	368 0.5×	246 0.4×	961 3.1×	495 1.7×	119 0.8×	21	2.2k
Atalanta Ghosh United States	13	420 0.6×	205 0.4×	267 0.9×	149 0.5×	138 0.9×	20	791

Countries citing papers authored by Niki Arya

Since Specialization

Citations

This map shows the geographic impact of Niki Arya's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Niki Arya with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Niki Arya more than expected).

Fields of papers citing papers by Niki Arya

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Niki Arya. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Niki Arya. The network helps show where Niki Arya may publish in the future.

Co-authorship network of co-authors of Niki Arya

This figure shows the co-authorship network connecting the top 25 collaborators of Niki Arya. A scholar is included among the top collaborators of Niki Arya based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Niki Arya. Niki Arya is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

14 of 14 papers shown

Singh, Dave, Fernando J. Martínez, John R. Hurst, et al.. (2024). Effect of Triple Therapy on Cardiovascular and Severe Cardiopulmonary Events in Chronic Obstructive Pulmonary Disease: A Post Hoc Analysis of a Randomized, Double-Blind, Phase 3 Clinical Trial (ETHOS). American Journal of Respiratory and Critical Care Medicine. 211(2). 205–214. 10 indexed citations

Singh, Dave, Mona Bafadhel, Karin Bowen, et al.. (2023). Step up to ICS/LAMA/LABA vs switch to LAMA/LABA in patients with COPD on ICS/LABA: post hoc analysis of KRONOS. PA4687–PA4687. 1 indexed citations

Araki, Eiichi, Chantal Mathieu, Toshihiko Shiraiwa, et al.. (2021). Long‐term (52‐week) efficacy and safety of dapagliflozin as an adjunct to insulin therapy in Japanese patients with type 1 diabetes: Subgroup analysis of the DEPICT ‐2 study. Diabetes Obesity and Metabolism. 23(7). 1496–1504. 6 indexed citations

Muskiet, Marcel H.A., Anne C. Hesp, Peter J. Greasley, et al.. (2020). Natriuretic Effect of Two Weeks of Dapagliflozin Treatment in Patients With Type 2 Diabetes and Preserved Kidney Function During Standardized Sodium Intake: Results of the DAPASALT Trial. Diabetes Care. 44(2). 440–447. 87 indexed citations

Phillip, Moshe, Chantal Mathieu, Marcus Lind, et al.. (2020). Long‐term efficacy and safety of dapagliflozin in patients with inadequately controlled type 1 diabetes: pooled 52‐week outcomes from the DEPICT ‐1 and ‐2 studies. Diabetes Obesity and Metabolism. 23(2). 549–560. 26 indexed citations

Mathieu, Chantal, Gottfried Rudofsky, Moshe Phillip, et al.. (2020). Long‐term efficacy and safety of dapagliflozin in patients with inadequately controlled type 1 diabetes (the DEPICT ‐2 study): 52‐week results from a randomized controlled trial. Diabetes Obesity and Metabolism. 22(9). 1516–1526. 43 indexed citations

Mathieu, Chantal, Paresh Dandona, Pieter Gillard, et al.. (2018). Efficacy and Safety of Dapagliflozin in Patients with Inadequately Controlled Type 1 Diabetes—DEPICT-2 Study. Diabetes. 67(Supplement_1). 10 indexed citations

Kosiborod, Mikhail, Matthew A. Cavender, Alex Z. Fu, et al.. (2017). Lower Risk of Heart Failure and Death in Patients Initiated on Sodium-Glucose Cotransporter-2 Inhibitors Versus Other Glucose-Lowering Drugs. Circulation. 136(3). 249–259. 604 indexed citations breakdown →

Ross, Lisa, Ivy Song, Niki Arya, et al.. (2016). No clinically significant pharmacokinetic interactions between dolutegravir and daclatasvir in healthy adult subjects. BMC Infectious Diseases. 16(1). 347–347. 5 indexed citations

10.

Barbour, April, Mindy Magee, Niki Arya, et al.. (2015). Utility of concentration-effect modeling and simulation in a thorough QT study of losmapimod. The Journal of Clinical Pharmacology. 55(6). 661–670. 5 indexed citations

11.

Koch, Kevin M., Geraldine Ferron‐Brady, Leanne Cartee, et al.. (2014). Bioequivalence study with lapatinib powder for oral suspension and the original tablet formulation in cancer patients. Clinical Pharmacology in Drug Development. 4(3). 203–209. 5 indexed citations

12.

Song, Ivy, Julie Borland, Niki Arya, Brian Wynne, & Stephen C. Piscitelli. (2014). Pharmacokinetics of dolutegravir when administered with mineral supplements in healthy adult subjects. The Journal of Clinical Pharmacology. 55(5). 490–496. 71 indexed citations

13.

Ascierto, Paolo A., David R. Minor, Antoni Ribas, et al.. (2013). Phase II Trial (BREAK-2) of the BRAF Inhibitor Dabrafenib (GSK2118436) in Patients With Metastatic Melanoma. Journal of Clinical Oncology. 31(26). 3205–3211. 338 indexed citations

14.

Burris, Howard A., Charles W. Taylor, Suzanne F. Jones, et al.. (2009). A Phase I and Pharmacokinetic Study of Oral Lapatinib Administered Once or Twice Daily in Patients with Solid Malignancies. Clinical Cancer Research. 15(21). 6702–6708. 83 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact